These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 506650)

  • 1. Low dose cyclophosphamide treatment on the myeloma.
    Isobe T; Horimatsu T; Matsumoto J; Kishihara M; Fujita T
    Nihon Ketsueki Gakkai Zasshi; 1979 Aug; 42(4):678-83. PubMed ID: 506650
    [No Abstract]   [Full Text] [Related]  

  • 2. Imuran-induced regression of plasma cell tumor MOPC-315.
    Schlossberg M; Hollander VP
    Cancer Res; 1973 Aug; 33(8):1953-6. PubMed ID: 4720804
    [No Abstract]   [Full Text] [Related]  

  • 3. [Generalized and solitary plasmacytomas. Analysis of 55 cases].
    Wildiers J; Drochmans A; Van der Schueren G
    Rev Med Liege; 1973 Jun; 28(12):454-9. PubMed ID: 4732148
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of malignant tumors through the internist].
    Schreml W; Kubanek B
    Aktuelle Probl Chir Orthop; 1977; 5():113-29. PubMed ID: 73352
    [No Abstract]   [Full Text] [Related]  

  • 5. Managing the complications of plasma cell myeloma.
    Cohen HJ; Rundles RW
    Arch Intern Med; 1975 Jan; 135(1):177-84. PubMed ID: 122891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytostatic treatment of plasmacytoma].
    Günther I; Gladitz G
    Z Gesamte Inn Med; 1972 Nov; 27(21):933-7. PubMed ID: 4662918
    [No Abstract]   [Full Text] [Related]  

  • 7. [A case of solitary myeloma (BJ-lambda) showing marked morphological changes].
    Fujii H; Seki S; Suyama Y; Shimizu T; Kano T; Yasuda N
    Gan No Rinsho; 1983 Apr; 29(4):A-22, 342-8. PubMed ID: 6854970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quantitative immunoglobulin determination in myeloma during cystostatic therapy].
    Klein WW
    Wien Med Wochenschr; 1972 Apr; 122(14):191-3. PubMed ID: 5014037
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)].
    Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F
    Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical utilization of plasmapheresis and cyclophosphamide in the treatment of malignant lymphoproliferative processes.
    Sakalová A; Gazová S; Hrubisko M; Gáliková J
    Neoplasma; 1973; 20(3):335-9. PubMed ID: 4199115
    [No Abstract]   [Full Text] [Related]  

  • 11. [A case of plasmocytic reticuloma treated periodically with big doses of alkeran and encorton (author's transl)].
    Bradowska M; Uransińki I
    Przegl Lek; 1975; 32(4):427-8. PubMed ID: 1129520
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of paraproteinemic diseases].
    Fölsch E
    Dtsch Med J; 1968 Aug; 19(15):517-22. PubMed ID: 4887941
    [No Abstract]   [Full Text] [Related]  

  • 13. The current status and future prospects of treatment for multiple myeloma.
    Durie BG; Salmon SE
    Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma cell myeloma showing progressive bone destruction during long-term clinical remission.
    Isobe T; Itoh T; Tomon M; Okimura Y; Kinoshita K; Fujita T
    Jpn J Med; 1983 Aug; 22(3):245-8. PubMed ID: 6620713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute new proliferation inparaproteinemic hemoblastoses during long-term treatment with cytostatic agents].
    Klemm D; Merker H; Westerhausen M
    Dtsch Med Wochenschr; 1968 Oct; 93(43):2063-4 passim. PubMed ID: 4971817
    [No Abstract]   [Full Text] [Related]  

  • 16. [Case of solitary bone plasmocytoma. 1st observation noted at Fort-Lamy (Chad) in a native].
    Sirol J; Laroche R; Huot D
    Bull Soc Pathol Exot Filiales; 1972; 65(6):893-900. PubMed ID: 4679274
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic results in paraproteinemic diseases and immunoreactions during treatment with cytostatic agents.
    Kessel M; Gerhartz H; Taguchi J; Taguchi T
    Antimicrob Agents Chemother (Bethesda); 1965; 5():518-23. PubMed ID: 5327521
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experiences with the combination of ethinyl estradiol and cyclophosphamide in the treatment of progressive metastasizing breast carcinomas in women].
    Nowakowski H; Rode P; Ruhstrat K
    Dtsch Med Wochenschr; 1971 Nov; 96(48):1855-60. PubMed ID: 5119931
    [No Abstract]   [Full Text] [Related]  

  • 19. Why R-CHOP for first line treatment of chronic lymphocytic leukemia?
    Smolej L
    Int J Lab Hematol; 2007 Dec; 29(6):478-9; author reply 479. PubMed ID: 17988306
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant treatment of osteogenic sarcoma with high-dose cyclophosphamide.
    Shepp M; Necheles TF; Banks HH; Oh WH; Zimbler S
    Cancer Treat Rep; 1978 Feb; 62(2):295-6. PubMed ID: 346220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.